Tariff Shock Threatens $200B U.S. MedTech Market
As new U.S. tariffs hit medical devices and equipment, raw materials, and essential components, iData Research warns of significant cost escalation and supply disruption across the MedTech sector. A recent U.S. court decision blocking the bulk of the proposed tariffs has only added further uncertainty, leaving manufacturers and suppliers navigating shifting trade policies with little clarity. With import duties potentially reaching up to 145%, and the potential expansion into pharmaceuticals, industry stakeholders must now reevaluate supplier networks, procurement models, and risk exposure across a $200B ecosystem. What’s Being Tariffed and Why It Matters Since early 2025, the U.S. has imposed tariffs on a broad range of medical imports and components, including: Tariff rates vary widely, starting at 10% and reaching up to 145% on certain Chinese imports. Additionally, exemptions under the United States-Mexico-Canada Agreement (USMCA) remain unstable, adding uncertainty to…

